Related Experiment Videos
Structure-based discovery of an organic compound that binds Bcl-2 protein and induces apoptosis of tumor cells
1Kimmel Cancer Center, Jefferson Medical College, Thomas Jefferson University, Philadelphia, PA 19107, USA.
Abstract:
Bcl-2 and related proteins are key regulators of apoptosis or programmed cell death implicated in human disease including cancer. We recently showed that cell-permeable Bcl-2 binding peptides could induce apoptosis of human myeloid leukemia in vitro and suppress its growth in severe combined immunodeficient mice. Here we report the discovery of HA14-1, a small molecule (molecular weight = 409) and nonpeptidic ligand of a Bcl-2 surface pocket, by using a computer screening strategy based on the predicted structure of Bcl-2 protein. In vitro binding studies demonstrated the interaction of HA14-1 with this Bcl-2 surface pocket that is essential for Bcl-2 biological function. HA14-1 effectively induced apoptosis of human acute myeloid leukemia (HL-60) cells overexpressing Bcl-2 protein that was associated with the decrease in mitochondrial membrane potential and activation of caspase-9 followed by caspase-3. Cytokine response modifier A, a potent inhibitor of Fas-mediated apoptosis, did not block apoptosis induced by HA14-1. Whereas HA14-1 strongly induced the death of NIH 3T3 (Apaf-1(+/+)) cells, it had little apoptotic effect on Apaf-1-deficient (Apaf-1(-/-)) mouse embryonic fibroblast cells. These data are consistent with a mechanism by which HA14-1 induces the activation of Apaf-1 and caspases, possibly by binding to Bcl-2 protein and inhibiting its function. The discovery of this cell-permeable molecule provides a chemical probe to study Bcl-2-regulated apoptotic pathways in vivo and could lead to the development of new therapeutic agents.
Insights
A novel small molecule, HA14-1, targets the Bcl-2 protein to induce apoptosis in cancer cells. This discovery offers a new chemical probe for studying programmed cell death and developing cancer therapeutics.
Area of Science:
- Molecular Biology
- Cell Biology
- Biochemistry
Background:
- Bcl-2 proteins regulate apoptosis, a process crucial in diseases like cancer.
- Previous research demonstrated that Bcl-2 binding peptides could induce apoptosis in leukemia cells.
Purpose of the Study:
- To discover a small molecule inhibitor of Bcl-2.
- To investigate the mechanism of action of the novel compound HA14-1.
- To evaluate HA14-1 as a potential therapeutic agent for cancer.
Main Methods:
- Structure-based computer screening to identify Bcl-2 ligands.
- In vitro binding assays to confirm interaction with Bcl-2.
- Apoptosis induction studies in human acute myeloid leukemia cells (HL-60) and mouse embryonic fibroblast cells (Apaf-1(+/+) and Apaf-1(-/-)).
- Assessment of mitochondrial membrane potential and caspase activation (caspase-9 and caspase-3).
Main Results:
- HA14-1, a nonpeptidic small molecule, was identified as a Bcl-2 ligand.
- HA14-1 induced apoptosis in Bcl-2-overexpressing leukemia cells, involving mitochondrial pathway activation.
- Apoptosis induction by HA14-1 was dependent on Apaf-1.
- HA14-1 did not inhibit Fas-mediated apoptosis.
Conclusions:
- HA14-1 functions as a Bcl-2 inhibitor, triggering apoptosis through Apaf-1 and caspase activation.
- This small molecule serves as a valuable chemical probe for in vivo studies of Bcl-2-regulated apoptosis.
- HA14-1 holds potential for the development of novel anti-cancer therapeutics.